{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:22:25Z","timestamp":1783167745961,"version":"3.54.6"},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.transci.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T05:57:15Z","timestamp":1534831035000},"page":"472-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Issues complicating precision dosing for factor VIII prophylaxis"],"prefix":"10.1016","volume":"57","author":[{"given":"Leonard A.","family":"Valentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Turecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Gritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saulius","family":"Butenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2018.07.007_bib0005","series-title":"MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). MASAC document 170","author":"National Hemophilia Foundation Medical and Scientific Advisory Council","year":"2007"},{"key":"10.1016\/j.transci.2018.07.007_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2018.07.007_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2516.9.s1.4.x","article-title":"Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective","volume":"9","author":"Bjorkman","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0020","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A","volume":"16","author":"Bjorkman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/hae.12438","article-title":"Considerations in individualizing prophylaxis in patients with haemophilia A","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2018.07.007_bib0035","first-page":"S32","article-title":"Development of a plasma- and albumin-free recombinant von Willebrand factor","volume":"29","author":"Turecek","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.transci.2018.07.007_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MBC.0b013e32831bc324","article-title":"One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin","volume":"20","author":"Lippi","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.transci.2018.07.007_bib0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0037-1619052","article-title":"Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype","volume":"30","author":"Oldenburg","year":"2010","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.transci.2018.07.007_bib0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0038-1646161","article-title":"Factor VIII structure and function","volume":"70","author":"Fay","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0060","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood.V92.11.3983","article-title":"The life cycle of coagulation factor VIII in view of its structure and function","volume":"92","author":"Lenting","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.transci.2018.07.007_bib0065","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2141.2006.06402.x","article-title":"In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results","volume":"136","author":"Rodgers","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2018.07.007_bib0070","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.23723","article-title":"Chromogenic factor VIII activity assay","volume":"89","author":"Moser","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2018.07.007_bib0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-2002-32658","article-title":"Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations","volume":"28","author":"Barrowcliffe","year":"2002","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 77","key":"10.1016\/j.transci.2018.07.007_bib0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ejh.12500","article-title":"One-stage vs. chromogenic assays in haemophilia A","volume":"94","author":"Potgieter","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2018.07.007_bib0085","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hae.13001","article-title":"A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE","volume":"22","author":"Turecek","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/hae.12446","article-title":"Assaying FVIII activity: one method is not enough, and never was","volume":"20","author":"Makris","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0095","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/jth.12167","article-title":"Recommendations on the potency labelling of factor VIII and factor IX concentrates","volume":"11","author":"Hubbard","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0100","first-page":"343","article-title":"A new approach to the determination of coagulation factors using chromogenic substrates","volume":"35","author":"Seghatchian","year":"1978","journal-title":"Med Lab Sci"},{"key":"10.1016\/j.transci.2018.07.007_bib0105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/hae.12296","article-title":"Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories","volume":"20","author":"Sommer","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2516.2010.02481.x","article-title":"International comparative field study of N8 evaluating factor VIII assay performance","volume":"17","author":"Viuff","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0115","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1111\/hae.12925","article-title":"BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study","volume":"22","author":"Kitchen","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0120","first-page":"59","article-title":"Characteristics of rFVIII-single chain in the one-stage and the chromogenic substrate assay: results of an international field study","volume":"22","author":"St. Ledger","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0125","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2516.2003.00773.x","article-title":"Standardization of FVIII & FIX assays","volume":"9","author":"Barrowcliffe","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0130","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1055\/s-0029-1245110","article-title":"Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation","volume":"35","author":"Kitchen","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0135","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1055\/s-0029-1245111","article-title":"The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation","volume":"35","author":"Meijer","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.transci.2018.07.007_bib0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2006.01262.x","article-title":"New approaches for measuring coagulation","volume":"12","author":"Barrowcliffe","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1309\/C8T8YNB4G3W45PRF","article-title":"Comparison of three methods for measuring factor VIII levels in plasma","volume":"120","author":"Chandler","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.transci.2018.07.007_bib0150","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/hae.12962","article-title":"Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII","volume":"22","author":"Kitchen","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0155","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/jth.13253","article-title":"A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays","volume":"14","author":"Kitchen","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0160","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2014-08-528398","article-title":"Diagnostic approach to von Willebrand disease","volume":"125","author":"Ng","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transci.2018.07.007_bib0165","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/pbc.25054","article-title":"Co-inheritance of mild hemophilia A and heterozygosity for type 2N von Willebrand disease: a diagnostic and therapeutic challenge","volume":"61","author":"Lindsay","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.transci.2018.07.007_bib0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1647295","article-title":"Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent","volume":"64","author":"Mazurier","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0175","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1538-7836.2006.01880.x","article-title":"Accuracy of FVIII: C assay by one-stage method can be improved using hemophilic plasma as diluent","volume":"4","author":"Cinotti","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0180","first-page":"321","article-title":"Preparation of factor-VIII-depleted plasma with antibodies and its use for the assay of factor VIII","volume":"20","author":"Rothschild","year":"1990","journal-title":"Haemostasis"},{"key":"10.1016\/j.transci.2018.07.007_bib0185","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0038-1649600","article-title":"Evaluation of factor VIII deficient plasmas","volume":"70","author":"Barrowcliffe","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0190","doi-asserted-by":"crossref","first-page":"e958","DOI":"10.1111\/j.1365-2516.2011.02523.x","article-title":"The use of the new ReFacto AF laboratory standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay","volume":"17","author":"Pouplard","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-2002-32659","article-title":"Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products","volume":"28","author":"Mikaelsson","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0200","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2516.2006.01420.x","article-title":"ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A","volume":"13","author":"Di Paola","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0205","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1046\/j.1538-7836.2003.00481.x","article-title":"A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards","volume":"1","author":"Morfini","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0037-1963(01)90104-0","article-title":"Measurement of factor VIII activity of B-domain deleted recombinant factor VIII","volume":"38","author":"Mikaelsson","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.transci.2018.07.007_bib0215","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1538-7836.2004.00657.x","article-title":"Field Study Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr factor VIII:C activity in hemophilic plasma using one-stage clotting assays","volume":"2","author":"Ingerslev","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0220","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2516.2011.02638.x","article-title":"The influence of prophylactic factor VIII in severe haemophilia A","volume":"18","author":"Gissel","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0225","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2516.2006.01396.x","article-title":"Different clinical phenotype in triplets with haemophilia A","volume":"13","author":"Barnes","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0230","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/j.1538-7836.2012.04905.x","article-title":"Age dependency of coagulation parameters during childhood and puberty","volume":"10","author":"Appel","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V80.1.25.25","article-title":"Measurement of basal levels of factor VIIa in hemophilia A and B patients","volume":"80","author":"Wildgoose","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.transci.2018.07.007_bib0240","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0245","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1055\/s-0033-1334863","article-title":"Diagnostic testing for mild hemophilia A in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays","volume":"39","author":"Duncan","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0250","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3324\/haematol.2013.088088","article-title":"Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A","volume":"98","author":"Bowyer","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2018.07.007_bib0255","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1365-2516.2008.01781.x","article-title":"One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype","volume":"14","author":"Cid","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0260","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1160\/TH13-08-0690","article-title":"Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays","volume":"111","author":"Pavlova","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0265","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2516.2008.01899.x","article-title":"Assay discrepancy in mild haemophilia A: entire population study in a National haemophilia Centre","volume":"15","author":"Poulsen","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0270","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1538-7836.2010.04174.x","article-title":"Prevalence, biological phenotype and genotype in moderate\/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity","volume":"9","author":"Trossaert","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2003-37936","article-title":"The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development","volume":"29","author":"Goodeve","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0280","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1532\/IJH97.05113","article-title":"Factor VIII structure and function","volume":"83","author":"Fay","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.transci.2018.07.007_bib0285","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6807-10-7","article-title":"Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study","volume":"10","author":"Venkateswarlu","year":"2010","journal-title":"BMC Struct Biol"},{"issue":"Suppl 4","key":"10.1016\/j.transci.2018.07.007_bib0290","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/hae.12405","article-title":"Changing paradigm of prophylaxis with longer acting factor concentrates","volume":"20","author":"Carcao","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0295","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2516.2008.01826.x","article-title":"Potency and mass of factor VIII in FVIII products","volume":"15","author":"Butenas","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0300","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/hae.12872","article-title":"Activation, activity and inactivation of factor VIII in factor VIII products","volume":"22","author":"Orfeo","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0310","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transci.2018.07.007_bib0315","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.161.3836.72","article-title":"Genetic control of drug levels in man: antipyrine","volume":"161","author":"Vesell","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.transci.2018.07.007_bib0320","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/clpt.2013.217","article-title":"Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology","volume":"95","author":"Kaddurah-Daouk","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2018.07.007_bib0325","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1111\/j.1753-4887.2012.00493.x","article-title":"Defining the human microbiome","volume":"70","author":"Ursell","year":"2012","journal-title":"Nutr Rev"},{"key":"10.1016\/j.transci.2018.07.007_bib0330","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/17425255.2016.1121234","article-title":"The influence of gut microbiota on drug metabolism and toxicity","volume":"12","author":"Li","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 5","key":"10.1016\/j.transci.2018.07.007_bib0335","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/hae.13012","article-title":"Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues","volume":"22","author":"Kitchen","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0340","first-page":"41","article-title":"Accuracy of published FVIII\/FIX:C assay result times: implications for pharmacokinetic (PK) guided dose predictions: a UK-PK study pilot","volume":"169","author":"Spencer Chapman","year":"2015","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2018.07.007_bib0345","first-page":"S32","article-title":"The principles of PK-tailored prophylaxis","volume":"33","author":"Reininger","year":"2013","journal-title":"Hamostaseologie"},{"issue":"Suppl 5","key":"10.1016\/j.transci.2018.07.007_bib0350","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2516.2010.02295.x","article-title":"New developments in laboratory diagnosis and monitoring","volume":"16","author":"Kitchen","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0355","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/hae.12374","article-title":"Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A","volume":"20","author":"Gu","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0360","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2008.62","article-title":"Effects of inflammation on pharmacokinetics\/pharmacodynamics: increasing recognition of its contribution to variability in response","volume":"83","author":"Schmith","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.transci.2018.07.007_bib0365","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1160\/TH11-05-0311","article-title":"Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks","volume":"106","author":"Naldini","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0370","first-page":"6","article-title":"Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis","volume":"343","author":"Rodriguez-Merchan","year":"1997","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.transci.2018.07.007_bib0375","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.ATV.0000168421.13467.82","article-title":"Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition","volume":"25","author":"Dahlback","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.transci.2018.07.007_bib0380","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","article-title":"The interactions between inflammation and coagulation","volume":"131","author":"Esmon","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2018.07.007_bib0385","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/bjsm.37.5.433","article-title":"Effects of strenuous exercise on haemostasis","volume":"37","author":"Smith","year":"2003","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.transci.2018.07.007_bib0390","first-page":"587","article-title":"The effect of aerobic and weight lifting exercise on blood clotting","volume":"14","author":"Saroglakis","year":"2014","journal-title":"J Physic Educ Sport"},{"key":"10.1016\/j.transci.2018.07.007_bib0395","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa075760","article-title":"Inhibitors of factor VIII in black patients with hemophilia","volume":"360","author":"Viel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2018.07.007_bib0400","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.12004","article-title":"F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) combined cohort","volume":"19","author":"Schwarz","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2018.07.007_bib0405","series-title":"MASAC statement regarding use of various clotting factor assays to monitor factor replacement therapy. MASAC document 228","author":"National Hemophilia Foundation Medical and Scientific Advisory Council","year":"2018"},{"key":"10.1016\/j.transci.2018.07.007_bib0410","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jcp.48.1.13","article-title":"Effect of thromboplastin and coagulometer interaction on the precision of the International Normalised Ratio","volume":"48","author":"Pi","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.transci.2018.07.007_bib0415","first-page":"836","article-title":"FVIII OS\/CS ratios for select novel recombinant FVIII replacement products measured in four FDA approved FVIII one-stage clot assay sytems and one chromogenic assay","volume":"13","author":"Tiefenbacher","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2018.07.007_bib0420","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0609.1984.tb02764.x","article-title":"Methodology of the one-stage assay of factor VIII (VIII:C)","volume":"41","author":"Over","year":"1984","journal-title":"Scand J Haematol Suppl"},{"key":"10.1016\/j.transci.2018.07.007_bib0425","series-title":"Prescribing information","author":"NUWIQ","year":"2017"},{"key":"10.1016\/j.transci.2018.07.007_bib0430","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.thromres.2012.08.311","article-title":"Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII","volume":"130","author":"Sandberg","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.transci.2018.07.007_bib0435","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/hae.13168","article-title":"Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study","volume":"23","author":"Hillarp","year":"2017","journal-title":"Haemophilia"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218302854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218302854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:02:18Z","timestamp":1720526538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050218302854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1473050218302854"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2018.07.007","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Issues complicating precision dosing for factor VIII prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Shire. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}